A randomized, controlled cross-over trial of dermally-applied lavender (Lavandula angustifolia) oil as a treatment of agitated behaviour in dementia

Daniel W O'Connor, Barbara Eppingstall, John Taffe, Eva S van der Ploeg, Daniel W O'Connor, Barbara Eppingstall, John Taffe, Eva S van der Ploeg

Abstract

Background: Lavender essential oil shows evidence of sedative properties in neurophysiological and animal studies but clinical trials of its effectiveness as a treatment of agitation in people with dementia have shown mixed results. Study methods have varied widely, however, making comparisons hazardous. To help remedy previous methodological shortcomings, we delivered high grade lavender oil in specified amounts to nursing home residents whose agitated behaviours were recorded objectively.

Methods: 64 nursing home residents with frequent physically agitated behaviours were entered into a randomized, single-blind cross-over trial of dermally-applied, neurophysiologically active, high purity 30% lavender oil versus an inactive control oil. A blinded observer counted the presence or absence of target behaviours and rated participants' predominant affect during each minute for 30 minutes prior to exposure and for 60 minutes afterwards.

Results: Lavender oil did not prove superior to the control oil in reducing the frequency of physically agitated behaviours or in improving participants' affect.

Conclusions: Studies of essential oils are constrained by their variable formulations and uncertain pharmacokinetics and so optimal dosing and delivery regimens remain speculative. Notwithstanding this, topically delivered, high strength, pure lavender oil had no discernible effect on affect and behaviour in a well-defined clinical sample.

Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN 12609000569202).

Figures

Figure 1
Figure 1
Study Flow Chart.
Figure 2
Figure 2
Mean scores before and after exposure to lavender and control oils. (a) Behaviour. (b) Positive Affect.

References

    1. Jäger W, Buchbauer G, Jorovetz L, Fritzer M. Percutaneous absorption of lavender oil from a massage oil. J Soc Cosmet Chem. 1992;43:49–54.
    1. Elisabetsky E, Marschner J, Souza DO. Effects of linalool on glutamatergic system in the rat cerebral cortex. Neurochem Res. 1995;20:461–465. doi: 10.1007/BF00973103.
    1. Huang L, Abuhamdah S, Howes MJR. et al.Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channels. J Pharm Pharmacol. 2008;60:1515–1522.
    1. Buchbauer G, Jirovetz L, Jager W, Plank C, Dietrich H. Fragrance compounds and essential oils with sedative properties. J Pharm Sci. 1993;82:660–664. doi: 10.1002/jps.2600820623.
    1. Umezu T. Behavioral effects of plant-derived essential oils in the Geller type conflict test in mice. Jpn J Pharmacol. 2000;83:150–153. doi: 10.1254/jjp.83.150.
    1. Linck VM, da Silva AL, Figueiró M. et al.Inhaled linalool-induced sedation in mice. Phytomed. 2009;16:303–307. doi: 10.1016/j.phymed.2008.08.001.
    1. Shiina Y, Funabashi N, Lee K. et al.Relaxation effects of lavender aromatherapy improve coronary flow velocity reserve in healthy men evaluated by transthoracic Doppler echocardiography. Int J Cardiol. 2008;129:193–197. doi: 10.1016/j.ijcard.2007.06.064.
    1. Field T, Field T, Cullen C. et al.Lavender bath oil reduces stress and crying and enhances sleep in very young infants. Early Hum Dev. 2008;84:399–401. doi: 10.1016/j.earlhumdev.2007.10.008.
    1. Kim JT, Ren CJ, Fielding GA. et al.Treatment of lavender aromatherapy in the post-anesthesia care unit reduces opioid requirements of morbidly obese patients undergoing laparoscopic adjustable gastric banding. Obes Surg. 2007;17:920–925. doi: 10.1007/s11695-007-9170-7.
    1. Kaspar S, Gastpar M, Müller WE. et al.Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wien Med Wochenschr. 2010;160:547–556. doi: 10.1007/s10354-010-0845-7.
    1. Bickers D, Calow P, Greim H. et al.A toxicogic and dermatologic assessment of linalool and related esters when used as fragrance ingredients. Food Chem Toxicol. 2003;41:919–942. doi: 10.1016/S0278-6915(03)00016-4.
    1. Holmes C, Hopkins V, Hensford C. et al.Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. Int J Geriatr Psychiatry. 2007;17:305–308.
    1. Lin PW, Chan W, Ng BF, Lam LC. Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviours in Chinese older persons with dementia: a cross-over randomised trial. Int J Geriatr Psychiatry. 2007;22:405–410. doi: 10.1002/gps.1688.
    1. Snow AL, Hovanec L, Brandt J. A controlled trial of aromatherapy of for agitation in nursing home patients with dementia. J Altern Complem Med. 2004;10:431–437. doi: 10.1089/1075553041323696.
    1. Smallwood J, Brown R, Coulter F, Irvine E. Aromatherapy and behaviour disturbances in dementia. Int J Geriatr Psychiatry. 2001;16:1010–1013. doi: 10.1002/gps.473.
    1. Gray SG, Clair AA. Influence of aromatherapy on medication administration to residential care residents with dementia and behavioral challenges. Am J Alzheimers Dis. 2002;17:169–174. doi: 10.1177/153331750201700305.
    1. Fujii M, Hatakeyama R, Fukuoka Y. et al.Lavender aroma therapy for behavioral and psychological symptoms in dementia patients. Geriatr Gerontol Int. 2008;8:136–138. doi: 10.1111/j.1447-0594.2008.00461.x.
    1. Holt FE, Birks TPH, Thorgrimsen LM, Aroma therapy for dementia. Cochrane Database Syst Rev. 2003. 10.1002/14651858.CD003150.
    1. O’Connor DW, Ames D, Gardner B, King M. Psychosocial treatments of behavior symptoms in dementia: a systematic review of reports meeting quality standards. Int Psychogeriatr. 2009;21:225–240. doi: 10.1017/S1041610208007588.
    1. Holmes C, Ballard C. Aromatherapy in dementia. Adv Psychiat Treat. 2004;10:296–300. doi: 10.1192/apt.10.4.296.
    1. Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Ageing. 2008;25:269–280. doi: 10.2165/00002512-200825040-00001.
    1. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Brit J Psychiat. 1982;140:566–572. doi: 10.1192/bjp.140.6.566.
    1. Van der Ploeg ES, Eppingstall B, O’Connor DW. The study protocol of a blinded, randomised controlled trial of lavender oil as a treatment of behavioural symptoms of dementia. BMC Geriatr. 2010;10:49. doi: 10.1186/1471-2318-10-49.
    1. Garland K, Beer E, Eppingstall B, O’Connor DW. A comparison of two treatments of agitated behavior in nursing home residents with behaviour: simulated family presence and preferred music. Am J Geriatr Psychiat. 2007;15:514–521. doi: 10.1097/01.JGP.0000249388.37080.b4.
    1. Lawton MP, van Haitsma K, Klapper J. Observed affect in nursing home residents with Alzheimer’s disease. J Gerontol. 1996;51:3–14.
    1. Folstein M, Folstein S, McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Cohen-Mansfield J. Agitated behaviors in the elderly: preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722–727.
    1. O’Connor DW, Ames D, Gardner B, King M. Psychosocial treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards. Int Psychogeriatr. 2009;21:241–251. doi: 10.1017/S1041610208008223.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner